Tests added high-flow oxygen therapy in people on long-term oxygen
Tests added high-flow oxygen with usual care in adults with lung disease needing home oxygen.
Plain-language title generated from the registry record
Registry title: Effect of HIgh-flow Therapy in Long-term Oxygen Therapy
Key facts
- Where
- Karlskrona and Örebro, SwedenSee the 2 sites
Where in Sweden
- Research Unit, Blekinge University of TechnologyKarlskrona, SwedenTaking people
- Department of Heart, Lung and Clinical Physiology, Örebro University HospitalÖrebro, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Skane University Hospital
- Trial code
- NCT06247397
- Record updated
- 21 May 2025
- Original description
This is a registry-based, randomized, controlled clinical trial of the effect of added high-flow oxygen therapy (using the device Lumis HFT) during one year in people with long-term oxygen therapy (LTOT) for chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD).Read full original descriptionShow less
Effect of HIgh-flow Therapy in Long-term Oxygen Therapy (HILOT): A Multicenter, Registry-based, Randomized Clinical Trial
This is a registry-based, randomized, controlled clinical trial of the effect of added high-flow oxygen therapy (using the device Lumis HFT) during one year in people with long-term oxygen therapy (LTOT) for chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD).
Inclusion: Age 40 years or older; Ongoing LTOT: prescribed for at least 15 hours per day; and since at least 28 days as registered in Swedevox; COPD or ILD as main underlying reason for LTOT; Oxygen concentrator as stationary oxygen source in the home including night-time; Body mass index (BMI) < 35 kg/m2.
Exclusion: Current or previous treatment with home HFOT; Current treatment with home mechanical ventilation; Current treatment with home CPAP; Strong clinical suspicion of obstructive sleep apnea (OSA) or obesity-related hypoventilation syndrome (OHS) (as judged by the responsible staff); Hospitalized during the last 2 weeks; Current smoking or contact with flames; Self-reported average use of the LTOT < 15h per day (24 hours); PaCO2 (breathing air at rest) > 8 kPa; Inability to participate in the study procedures (as judged by the staff); Not eligible for continuing LTOT due to other reason (as judged by the staff); Expected survival less than 3 months (as judged by the staff).